All In Biotech

Drug Trial Radar · NCT07465835

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Feb 17, 2026

Primary completion

Jun 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Electra Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Mar 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.

Conditions

  • T Cell Malignancies

Interventions

  • ELA026Drug

    Weekly maintenance dosing via subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTs and treatment emergent adverse events (TEAEs), including serious adverse advents (SAEs)Time frame: DLTs from baseline to DLT window (35 days) and SAEs from baseline through end of safety follow up (approximately 28 weeks for those participants not continuing to optional extension phase)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Yale New Haven Hospital

    New Haven, Connecticut · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • START, Midwest

    Grand Rapids, Michigan · Recruiting

  • Memorial Sloan Kettering

    New York, New York · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.